This is a Phase I/II international, multicenter study of the combination of AZD2014 and palbociclib on a background of 500 mg fulvestrant (referred to as the triplet) in postmenopausal women with locally advanced/metastatic estrogen receptor positive (ER+) breast cancer. The study consists of three parts: